A new method to personalize treatment for iodine-refractory thyroid cancer
A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer
This study is looking for better ways to treat patients with iodine-refractory thyroid cancer by creating tiny models of the cancer to test new treatments that might help the cancer cells absorb radioactive iodine again, which could lead to more personalized and effective care for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11075322 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for patients with iodine-refractory thyroid cancer, a condition where cancer cells can no longer absorb radioactive iodine, which is crucial for effective treatment. The project aims to develop organoid models of papillary thyroid carcinoma to test and optimize redifferentiation agents that can restore the cancer cells' ability to uptake radioactive iodine. By creating a high-throughput assay, the researchers will be able to analyze thousands of tumor organoid cultures to identify the most effective treatments for individual patients. This personalized approach could lead to better management of the disease and improved outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with iodine-refractory thyroid cancer who have limited treatment options.
Not a fit: Patients with early-stage thyroid cancer or those who are not iodine-refractory may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance treatment options and survival rates for patients with iodine-refractory thyroid cancer.
How similar studies have performed: Other research has shown promise in using redifferentiation strategies for similar conditions, indicating potential for success in this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Pratx, Guillem — Stanford University
- Study coordinator: Pratx, Guillem
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.